RECRUITINGOBSERVATIONAL

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone

About This Trial

This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar 2. With or without cognitive involvement 3. Willing to participate 4. On no experimental treatment 5. Ages 18 - 85 6. No prior exposure to Edaravone (Radicava) 7. On a stable dose of Riluzole for 30 days or off Riluzole 8. Male or female 9. Females of childbearing age must use contraception Who Should NOT Join This Trial: 1. Unstable medical illness 2. Abnormal liver function (\>2x ULN) 3. Unlikely to survive for 26 weeks Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar 2. With or without cognitive involvement 3. Willing to participate 4. On no experimental treatment 5. Ages 18 - 85 6. No prior exposure to Edaravone (Radicava) 7. On a stable dose of Riluzole for 30 days or off Riluzole 8. Male or female 9. Females of childbearing age must use contraception Exclusion Criteria: 1. Unstable medical illness 2. Abnormal liver function (\>2x ULN) 3. Unlikely to survive for 26 weeks

Treatments Being Tested

OTHER

Sample Collection

The investigators will be collecting blood, urine, and spinal fluid samples.

Locations (1)

Loma Linda University

Loma Linda, California, United States